Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer.

Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer.

老虎证券2026/03/18 10:24

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Preliminary data show that in the subgroup of patients without the HLA-A*02 genotype, GP2 treatment can significantly reduce breast cancer recurrence rates by 70%-80%. This data comes from a follow-up analysis of a Phase IIb clinical trial involving approximately 160 HER2/neu-positive breast cancer patients who have completed standard treatment. Genotyping and Efficacy Correlation Highlighted GP2 is a peptide immunotherapy targeting the HER2/neu protein, activating specific T cells to attack tumor cells expressing HER2. This analysis focuses on the impact of different HLA genotypes on efficacy: in the HLA-A*02-positive group, which accounts for about 60% of the patient population, GP2 previously showed zero recurrence rate; while the current non-HLA-A*02 group (about 40%) also demonstrated significant efficacy, with safety data consistent with previous results. This suggests that GP2 may possess broad-spectrum anti-tumor potential across genetic subtypes, providing a new direction for personalized cancer immunotherapy. Industry Background and Competitive Landscape Currently, the global breast cancer immunotherapy field is still dominated by giants such as Roche and Merck, but there remains a huge unmet need for adjuvant therapies targeting high-risk populations. If GP2 proves its efficacy in Phase III clinical trials, it is expected to become the first immunotherapy focused on preventing recurrence of HER2-positive breast cancer. It is noteworthy that recently, pharmaceutical companies such as Pfizer and Bristol Myers Squibb have increased their investment in the oncology immunotherapy sector, but mostly focus on PD-1/PD-L1 inhibitor combination therapies. GP2’s differentiated positioning may create a unique space for its commercialization. Capital Market Response and Subsequent Milestones Although this data is still from early analysis, after the news was released, GLSI’s stock price fluctuated significantly in after-hours trading. Analysts pointed out that the key validation point lies in the design and patient enrollment progress of the Phase III clinical trial starting in 2024. If subsequent data can maintain the current level of efficacy, GP2 is expected to submit a Biologics License Application before 2026. JPMorgan’s latest research report highlights that GP2’s market value catalysts include details of the Phase III clinical protocol, potential partner movements, and exploration of expanding indications to other HER2-positive tumors.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 9 - ** Shares of Australian Maas Group (MGH.AX) have fallen more than 27% so far this week and are set for their worst weekly performance if the downward trend continues. ** On Thursday, media reported that Firmus, backed by Nvidia, might reduce the size of its AUD 5 billion Australian IPO (link), sparking investor concerns and leading to a 30% plunge in shares of construction services provider MGH. ** MGH holds a 3.2% stake in this AI data center operator. ** MGH suspended trading on Friday (link), pending an announcement related to Firmus. Firmus has shelved its AUD 5 billion listing plan due to market volatility and conditions. ** Before the suspension, MGH's shares had already fallen over 8% this year. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. This automated translation may contain inaccuracies or omit the desired context; Reuters does not guarantee the accuracy of automated translations and provides them solely for reader convenience. Reuters accepts no liability for any harm or loss caused by the use of automated translations.)

路透社•2026/10/09 01:26

Apple to launch dual products in October: First touch-screen MacBook and new iPad mini to debut simultaneously

Apple is planning to hold its second product launch event of the month around October 27, where it will introduce its first-ever touchscreen MacBook Pro (featuring an OLED display and the “Dynamic Island” interface), a new iPad mini (also upgraded with OLED and a repositioned camera), as well as a 14-inch MacBook Pro and iMac powered by the M6 chip. These are the first major products overseen by the new CEO, John Ternus.

华尔街见闻•2026/10/09 01:01

BUZZ - Driven by active trading, the Australian Securities Exchange (ASX) is on track for its best week in two months

October 9 – The stock price of ASX ASX.AX, the operator of the Australian Securities Exchange, has risen more than 3.8% so far this week, on track for its best weekly performance since early August. On Thursday, Citi raised its annual earnings per share (EPS) forecast for ASX by 2%, citing continued strong trading activity. On Friday, the stock was up as much as 0.3% to 60.79 AUD. Citi also holds a positive view of ASX’s new CEO, Anthony Attia, agreeing with his approach of bringing in external talent and modernizing technology. Including the latest gain, the stock is up 18% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of the translation. The automated translation is provided solely for the convenience of readers, and Reuters accepts no liability for any damage or loss arising from the use of the automated translation.)

路透社•2026/10/09 00:56